Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 9:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,064 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: System; Sclerosis Clear all
Completed No phase listed Observational Accepts healthy volunteers

Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?

NCT02588053
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Sep 9, 2026, 9:05 AM EDT
Withdrawn Phase 2 Interventional

Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis

NCT01047072
View directory record Official record
Conditions
Systemic Scleroderma
Interventions
fludarabine phosphate, total-body irradiation, tacrolimus, mycophenolate mofetil, rituximab, cyclophosphamide, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Drug · Radiation · Biological + 1 more
Lead sponsor
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Sep 9, 2026, 9:05 AM EDT
Terminated No phase listed Observational

Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance

NCT01156298
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 85 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Sep 9, 2026, 9:05 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Prospective Investigation of Multiple Sclerosis in the Three Rivers Region

NCT02994121
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
7 Years and older
Enrollment
7,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2047
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Sep 9, 2026, 9:05 AM EDT
Completed Not applicable Interventional

Rehabilitation for Arm Coordination and Hand Movement in Systemic Sclerosis

NCT03482219
View directory record Official record
Conditions
Systemic Sclerosis, SSc
Interventions
Occupational therapy, Home app intervention
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Sep 9, 2026, 9:05 AM EDT
Terminated Phase 2 Interventional Results available

Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex

NCT03363763
View directory record Official record
Conditions
Angiofibroma of Face, Tuberous Sclerosis
Interventions
Sirolimus 0.2%, Sirolimus 0.4%, Placebo ointment
Drug
Lead sponsor
Aucta Pharmaceuticals, Inc
Industry
Eligibility
2 Years to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Sep 9, 2026, 9:05 AM EDT
Terminated Not applicable Interventional Results available

Feasibility of Remote Exercise Training for Hispanics/Latinos With MS

NCT05998616
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Exercise Training Program, Flexibility Program
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 9, 2026, 9:05 AM EDT
Completed Phase 2 Interventional

Auditory Function in Patients With and Without Multiple Sclerosis

NCT00037947
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Hearing in Multiple Sclerosis
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 3, 2008 · Synced Sep 9, 2026, 9:05 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent

NCT04933552
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Siponimod
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Female only
Enrollment
867 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2032
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 9, 2026, 9:05 AM EDT
Not listed Not applicable Interventional

KITAMS: Kinesio Tape and Physical Function in Persons With Multiples Sclerosis

NCT03804047
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
kinesio tape
Other
Lead sponsor
Northern Illinois University
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
DeKalb, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Sep 9, 2026, 9:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI)

NCT01356134
View directory record Official record
Conditions
Ehlers-Danlos Syndrome, Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Genetic Disease Investigators
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Colleyville, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Sep 9, 2026, 9:05 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effectiveness of Task Specific Home Exercise Program

NCT06486116
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Task Specific Physical Therapy Home Program
Behavioral
Lead sponsor
New York Presbyterian Brooklyn Methodist Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 9, 2026, 9:05 AM EDT
Completed Phase 2 Interventional Results available

BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis

NCT01156311
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
16
States / cities
Gilbert, Arizona • Phoenix, Arizona • Danbury, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 9, 2026, 9:05 AM EDT
Withdrawn Phase 2Phase 3 Interventional

CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH

NCT03726398
View directory record Official record
Conditions
Interstitial Lung Disease, Scleroderma, Pulmonary Hypertension
Interventions
Opsumit 10 Mg Tablet
Drug
Lead sponsor
Franz Rischard, DO
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Sep 9, 2026, 9:05 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis

NCT02465437
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
JBT-101, Placebo, Part B Open-Label Extension
Drug
Lead sponsor
Corbus Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Sep 9, 2026, 9:05 AM EDT
Terminated Phase 2 Interventional Results available

An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)

NCT05626751
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
Interventions
HZN-825
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 9, 2026, 9:05 AM EDT
Completed Phase 3 Interventional

BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients

NCT00099502
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Interferon beta-1b (Betaferon/Betaseron, BAY86-5046), Copaxone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
2,244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
57
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2008 · Synced Sep 9, 2026, 9:05 AM EDT
Completed Phase 1 Interventional

Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis

NCT00017628
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
cyclophosphamide, filgrastim, methylprednisolone, Autologous Stem Cell Transplantation
Drug · Procedure
Lead sponsor
Northwestern Memorial Hospital
Other
Eligibility
0 Years to 59 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 9, 2026, 9:05 AM EDT
Completed No phase listed Observational

ETNA-MS Device Validation Study

NCT06256731
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Eye-Tracking
Device
Lead sponsor
Innodem Neurosciences
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Phoenix, Arizona • Farmington Hills, Michigan • Owosso, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 9, 2026, 9:05 AM EDT
Completed No phase listed Observational

CLUE Study: Connective Tissue Disease Leg Ulcer Etiology Study

NCT00522002
View directory record Official record
Conditions
Connective Tissue Diseases, Blood Coagulation Disorders, Leg Ulcers, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Scleroderma, Mixed Connective Tissue Disease
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Sep 9, 2026, 9:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Testosterone Treatment for Multiple Sclerosis

NCT00405353
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Androgel 10 grams of gel containing 100 mg of testosterone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Sep 9, 2026, 9:05 AM EDT
Completed No phase listed Observational

Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy

NCT00336557
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
NAbs testing
Procedure
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
49
States / cities
Phoenix, Arizona • Berkley, California • Fresno, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Sep 9, 2026, 9:05 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

NCT04544436
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab, Antihistamine, Methylprednisolone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
25
States / cities
Cullman, Alabama • Homewood, Alabama • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 9, 2026, 9:05 AM EDT
Completed No phase listed Observational

Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in MS

NCT02965170
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Rocky Mountain MS Research Group, LLC
Other
Eligibility
18 Years to 80 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 9, 2026, 9:05 AM EDT